13-Jan-2026 3:05 PM CST - Business Wire Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $14
16-Dec-2025 6:00 AM CST - Business Wire Glaukos Announces Participation in J.P. Morgan Healthcare Conference Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA. A live and archived webcast for these events, where applicable, will be available in
3-Nov-2025 6:00 AM CST - Business Wire Glaukos Announces Participation in Upcoming Investor Conferences Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 11, 2025, at 10:15 a.m. ET in Palm Beach, FL Stifel Healthcare Conference on Wednesday, November 12, 20
29-Oct-2025 3:05 PM CST - Business Wire Glaukos Announces Third Quarter 2025 Financial Results Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2025. Key highlights include: Record net sales of $133.5 million in Q3 2025 increased 38% year-over-year on a reported basis and 37% year-over-year on a constant currency basis. Glaucoma recor
20-Oct-2025 6:00 AM CST - Business Wire Glaukos Announces FDA Approval of Epioxa Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved its Epioxa HD / Epioxa (Epioxa) New Drug Application (NDA). Epioxa is a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease tha
8-Oct-2025 6:00 AM CST - Business Wire Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2025 financial results after the market close on Wednesday, October 29, 2025. The companys management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 29, 2025. A link t
13-Aug-2025 6:00 AM CST - Business Wire Glaukos Announces Participation in Wells Fargo Healthcare Conference Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors
30-Jul-2025 3:05 PM CST - Business Wire Glaukos Announces Second Quarter 2025 Financial Results Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include: Record net sales of $124.1 million in Q2 2025 increased 30% year-over-year on a reported basis and 29% year-over-year on a constant currency basis. Glaucoma record net
9-Jul-2025 6:00 AM CST - Business Wire Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30 Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2025 financial results after the market close on Wednesday, July 30, 2025. The companys management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 30, 2025. A link to the
13-Jan-2026 3:05 PM CST - Business Wire Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $14
16-Dec-2025 6:00 AM CST - Business Wire Glaukos Announces Participation in J.P. Morgan Healthcare Conference Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA. A live and archived webcast for these events, where applicable, will be available in
3-Nov-2025 6:00 AM CST - Business Wire Glaukos Announces Participation in Upcoming Investor Conferences Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 11, 2025, at 10:15 a.m. ET in Palm Beach, FL Stifel Healthcare Conference on Wednesday, November 12, 20
29-Oct-2025 3:05 PM CST - Business Wire Glaukos Announces Third Quarter 2025 Financial Results Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2025. Key highlights include: Record net sales of $133.5 million in Q3 2025 increased 38% year-over-year on a reported basis and 37% year-over-year on a constant currency basis. Glaucoma recor
20-Oct-2025 6:00 AM CST - Business Wire Glaukos Announces FDA Approval of Epioxa Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved its Epioxa HD / Epioxa (Epioxa) New Drug Application (NDA). Epioxa is a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease tha
8-Oct-2025 6:00 AM CST - Business Wire Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2025 financial results after the market close on Wednesday, October 29, 2025. The companys management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 29, 2025. A link t
13-Aug-2025 6:00 AM CST - Business Wire Glaukos Announces Participation in Wells Fargo Healthcare Conference Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors
30-Jul-2025 3:05 PM CST - Business Wire Glaukos Announces Second Quarter 2025 Financial Results Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include: Record net sales of $124.1 million in Q2 2025 increased 30% year-over-year on a reported basis and 29% year-over-year on a constant currency basis. Glaucoma record net
9-Jul-2025 6:00 AM CST - Business Wire Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30 Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2025 financial results after the market close on Wednesday, July 30, 2025. The companys management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 30, 2025. A link to the
